Neuroform Atlas Stent System for the treatment of intracranial aneurysm: primary results of the Atlas Humanitarian Device Exemption cohort
Authors
Jankowitz, Brian T.Hanel, Ricardo
Jadhav, Ashutosh P.
Loy, David N.
Frei, Donald
Siddiqui, Adnan H.
Puri, Ajit S.
Khaldi, Ahmad
Turk, Aquilla S.
Malek, Adel M.
Sauvageau, Eric
Hetts, Steven W.
Zaidat, Osama O.
UMass Chan Affiliations
Department of RadiologyDocument Type
Journal ArticlePublication Date
2019-01-22Keywords
ATLASatlas stent
cerebral aneurysm
neuroform
stent-assisted coiling
wide-neck aneurysm
Cardiovascular Diseases
Nervous System Diseases
Neurology
Radiology
Surgery
Surgical Procedures, Operative
Metadata
Show full item recordAbstract
BACKGROUND AND OBJECTIVE: Stent-assisted coil embolization is a well-established treatment of intracranial wide-necked aneurysms. The Neuroform Atlas Stent System is a new generation microstent designed to enhance coil support, conformability, deliverability, and improve deployment accuracy. We present the 1-year efficacy and angiographic results of the Humanitarian Device Exemption (HDE) cohort from the Atlas Investigational Device Exemption (IDE) clinical trial. METHOD: The Atlas IDE trial is a prospective, multicenter, single-arm, open-label study of unruptured wide-necked intracranial aneurysms treated with the Neuroform Atlas stent and approved coils. The primary efficacy endpoint was the rate of 12-month complete aneurysm angiographic occlusion (Raymond class I) without target aneurysm retreatment or significant parent artery stenosis ( > 50%) at the target location. The primary safety endpoint was the rate of major ipsilateral stroke or neurological death within 12 months. Imaging core laboratory and Clinical EventsCommittee adjudicated the primary endpoints. RESULTS: 30 patients were enrolled at eight US centers, with 27 patients completing the 12-month angiographic follow-up. The mean age was 59.4+/-11.8 years and 24/30 patients (80%) were women. The mean aneurysm size was 5.3+/-1.7 mm and the dome:neck ratio was 1.1+/-0.2. Procedural technical success of Neuroform Atlas Stent deployment was 100%. 27 patients completed 12-month angiographic follow-up and 30 patients completed their 6-month follow-up. When applying the last observation carried forward method, the primary efficacy endpoint was observed in 26/30 patients (86.7%, 95% CI 69.3% to 96.2%) compared with 25/27 patients (92.6%, 95% CI 75.7% to 99.1%) who completed the 12-month angiographic follow-up. The primary safety endpoint of stroke occurred in one patient (3.3%), who made a complete clinical recovery at discharge. There were no neurological deaths. CONCLUSION: The Neuroform Atlas stent in conjunction with coils demonstrated a high rate of complete aneurysm occlusion at 12-month angiographic follow-up, with an improved safety profile in the HDE cohort. CLINICAL TRIALGOV REGISTRATION NUMBER: NCT0234058.Source
J Neurointerv Surg. 2019 Jan 22. pii: neurintsurg-2018-014455. doi: 10.1136/neurintsurg-2018-014455. [Epub ahead of print] Link to article on publisher's site
DOI
10.1136/neurintsurg-2018-014455Permanent Link to this Item
http://hdl.handle.net/20.500.14038/48341PubMed ID
30670625Related Resources
Rights
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.Distribution License
http://creativecommons.org/licenses/by-nc/4.0/ae974a485f413a2113503eed53cd6c53
10.1136/neurintsurg-2018-014455
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.